SVRA - Savara Inc logo

SVRA

Savara Inc

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Its lead product, molgramostim, is an inhaled therapy in Phase 3 for autoimmune pulmonary alveolar proteinosis.

⚕️ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 20 years ago $1today

Score Overview

1 Year
Score
Net Growth-8.96%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score1.1
Net Growth-201.02%
Net Trend20%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-32x
Net Trend31%
Net Income Consistency
Rev Growth
Rev Trend21%
Revenue Consistency

See the full market ranking →

Savara Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 257K to $ 0.00 and net income went from -$ 49M to -$ 118M. Revenue increased in 0 of those 5 years; net income in 1.

Savara Inc currently holds a 5-year HDB Score of 1.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 5.70
1 Year2025-08-12
$ 2.58120.93%
5 Years2021-08-12
$ 1.21371.07%
10 Years2016-08-12
$ 27.29-79.12%
20 Years2006-08-11
$ 5.2K-99.89%
All Time2017-06-01
$ 5.1610.47%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 129M$ 202M
2025$ 0.00-$ 118M$ 235M
2024$ 0.00-$ 95M$ 196M
2023$ 0.00-$ 54M$ 162M
2022$ 0.00-$ 38M$ 125M
2021$ 1K-$ 43M$ 161M
2020$ 257K-$ 49M$ 82M
2019$ 0.00-$ 78M$ 121M
2018$ 0.00-$ 61M$ 110M
IPO2017$ 0.00-$ 29M$ 94M
2016$ 400K-$ 10M$ 13M
2015$ 54.00-$ 39M$ 40M
2014$ 1.55K-$ 28M$ 57M
2013$ 0.00-$ 21M$ 44M
2012$ 0.00-$ 15M$ 36M
2011$ 0.00-$ 13M$ 50M
2010$ 488.96K-$ 8M$ 27M
2009$ 300K-$ 11M$ 8M
2008$ 500K-$ 26M$ 9M
2007$ 500K-$ 22M$ 33M
2006-$ 29M$ 51M
2005$ 496.06K-$ 24M$ 22M
2004-$ 6M$ 13M
2003-$ 2M$ 4M
2002-$ 2M$ 103.93K
2001-$ 16M$ 164.48K
2000-$ 3M$ 1M

Explore beyond SVRA

You're looking at Savara Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies